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Abstract: Telehealth programs to promote early identification and timely self-management 
of acute exacerbations of chronic obstructive pulmonary diseases (AECOPDs) have yielded 
disappointing results, in part, because parameters monitored (symptoms, pulse oximetry, and 
spirometry) are weak predictors of exacerbations.
Purpose: Breathing rate (BR) rises during AECOPD and may be a promising predictor. Devices 
suitable for home use to measure BR have recently become available, but their accuracy, accept-
ability, and ability to detect changes in people with COPD is not known.
Patients and methods: We compared five BR monitors, which used different monitoring 
technologies, with a gold standard (Oxycon Mobile®; CareFusion®, a subsidiary of Becton Dick-
inson, San Diego, CA, USA). The monitors were validated in 21 stable COPD patients during 
a 57-min “activities of daily living protocol” in a laboratory setting. The two best performing 
monitors were then tested in a 14-day trial in a home setting in 23 stable COPD patients to 
determine patient acceptability and reliability of signal. Acceptability was explored in qualita-
tive interviews. The better performing monitor was then given to 18 patients recruited during an 
AECOPD who wore the monitor to observe BR during the recovery phase of an AECOPD.
Results: While two monitors demonstrated acceptable accuracy compared with the gold 
standard, some participants found them intrusive particularly when ill with an exacerbation, 
limiting their potential utility in acute situations. A reduction in resting BR during the recovery 
from an AECOPD was observed in some, but not in all participants and there was considerable 
day-to-day individual variation.
Conclusion: Resting BR shows some promise in identifying exacerbations; however, further 
prospective study to assess this is required. 
Keywords: COPD exacerbation, telemedicine, COPD management, heart rate
Introduction
Worldwide, 65 million people live with COPD, and this number is predicted to increase 
by one-third by 2030.1 Self-management, supporting early identification, and timely 
treatment of acute exacerbations of COPD (AECOPD) is promoted to reduce hospital 
admissions, improve time to recovery, slow disease deterioration, and reduce health 
care use/cost.2–8 As .50% of the costs of COPD are due to hospital admissions, reduc-
ing these is a priority for health services.9
Globally, health care policies encourage telehealthcare-supported self-manage-
ment of long-term conditions, but current telehealth systems are limited by what can 
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be feasibly monitored in a domestic setting and in terms 
of cost-effectively preventing hospital admissions; results 
have been disappointing.10–15 This, in part, is due to the 
poor predictive ability of currently available physiological 
measurements and symptom scores.16 There is a need for 
convenient and reliable measures that predict AECOPD. 
Breathing rate (BR) increases early during AECOPD and 
is thus a potential target for telemonitoring for the early 
identification and treatment of AECOPD to prevent hospital 
admission.17
Historically, methods of measuring BR were intrusive 
and unsuitable for routine domiciliary use, but recently less 
obtrusive technologies have been developed, initially for use 
in sports and military environments. However, it is not clear 
if devices that work well in fit people will also be reliable in 
breathless people with COPD. Identification and validation of 
devices that can reliably and conveniently be used to monitor 
BR in patients with COPD is a first step in the assessment of 
BR as a potential early indicator of AECOPD.
This study was conducted in three phases. In phase I, we 
aimed to select and validate commercially available devices 
to determine if they could accurately monitor BR in people 
with a broad spectrum of COPD severity. In phase II, the 
two best performing monitors were used at home by patients 
and their acceptability and perceived utility assessed quali-
tatively. In phase III, we aimed to examine the ability of the 
best performing device to detect changes in BR as patients 
recovered from an acute exacerbation with the aim, that if it 
proved feasible to detect such changes, to carry out a future 
prospective study in a group of patients at risk of AECOPD 
to see if BR changes might be useful in identifying exacerba-
tions at an early stage.
Methods
approvals
The study was approved by the National Health Service (NHS) 
Health Research Authority South East Scotland Research 
Ethics Committee (13/SS/0114, 13/SS/0206, 14/SS/0043) and 
received governance approval from NHS Lothian.
Patient recruitment
We recruited patients with moderate-to-very severe COPD 
as defined in the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines.18 In phases I and II, par-
ticipants were recruited from respiratory outpatient clinics. 
They had to be clinically stable and free of exacerbations for 
at least 6 weeks prior to recruitment. Patients were recruited 
for phase III during an acute exacerbation either as hospital 
inpatients or from the local community respiratory team at 
home. Patients were excluded if they had terminal prognosis, 
if they had a heart pacemaker or automatic defibrillator, or 
if they had evidence of skin irritation (several devices were 
applied to skin). Written informed consent was taken from 
all patients for this study.
study Design
Phase I: validation of Br measurements in a 
laboratory setting
Characterization of participants
Participants undertook spirometry (Alpha Spirometer; 
Vitalograph, Buckingham, Buckinghamshire, UK) accord-
ing to American Thoracic Society/European Respiratory 
Society standards before and after the administration of 
2.5 mg of nebulized salbutamol.19 As a measure of muscle 
function, muscle strength was assessed as the maximal 
isometric quadriceps voluntary contraction using a strain 
gauge dynamometer (Chatillon®; K-MSC 500, Ametek, 
FL, USA).20,21
Participants wore four BR monitors simultaneously in 
contact with the skin while being video-monitored by a fifth. 
The monitors’ technical characteristics and the pseudonyms 
used in this study are shown in Table 1. Briefly, these were 
a chest mounted electrode array (measuring impedance), a 
finger mounted photoplethysmography system (measuring 
beat-to-beat variation), a camera mounted distance photo-
plethysmography device (measuring chest wall movements 
and skin color change), an upper abdomen mounted triaxial 
accelerometer, and a chest worn pressure sensor pad on 
elastic band, which also included a triaxial accelerometer 
and electrocardiograph.
Patients were asked to perform a set of activities dur-
ing a standardized protocol of activities over 57-min, 
chosen to be representative of daily life activities, such 
as sitting, standing, walking, lifting, and climbing stairs. 
The protocol combined activities of different intensities 
and resting periods to stimulate changes in BR (Table 2). 
The aim was to assess the accuracy of the monitors in 
measuring BR and in detecting changes of different 
magnitudes in BR.
The gold standard against which the five monitors 
were tested was a metabolic system (Oxycon Mobile®; 
CareFusion®, a subsidiary of Becton Dickinson, San Diego, 
CA, USA) that the patients also wore together with an oxygen 
saturation ear probe and a Polar T31 (Polar Electro [UK] 
Ltd, Warwick, Warwickshire, UK) coded transmitter belt 
for heart rate (HR) monitoring. The Oxycon was attached to 
the upper chest with a harness that caused minimal discom-
fort due to its low weight (950 g). A facemask with a dead 
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space ,30 mL (Hans Rudolph Inc, Kansas City MO, USA) 
was used. The location of the Oxycon device did not interfere 
with the functioning of the BR monitors. The Oxycon device 
was calibrated (a two-point gas calibration) prior to each 
test. As part of the calibration process, the internal clocks 
of all the BR monitors were synchronized with the Oxycon 
to ensure optimal alignment of the different measurements. 
The Oxycon continuously measured oxygen consumption 
(VO
2
), carbon dioxide production (VCO
2
), HR, BR, and tidal 
volume. Breath-by-breath measurements were averaged over 
1-min intervals.
Monitor 5 (Chest-band) also provided data on HR and 
physical activity level (PAL). Comparison of the HR provided 
by the Monitor 5 (Chest-band) with the HR provided by Oxy-
con was used to validate this parameter. To validate PAL 
provided by the Monitor 5 (Chest-band), Oxycon VO
2
 values 
were divided by participants’ body weight and converted to 
metabolic equivalents of task (METs).22 These METs energy 
expenditure estimates were used as a measure of energy 
expenditure to validate PAL provided by Monitor 5 (Chest-
band), and to identify the BR data recorded when patients 
were at rest (see the file online supplement in Supplementary 
material for further detail).
In addition, during this phase, patients were asked which 
monitor they preferred. Data were downloaded from all the 
devices to a personal computer for analysis.
analysis
In phase I, minute-by-minute data from all devices were com-
piled for each patient in one database, and synchronization 
was verified by inspection of the curves of the VO
2
 in relation 
to the activities performed to ensure the best fit between the 
monitors on a patient-by-patient basis. Participant differ-
ences between the BR measured with each trial device and 
the Oxycon device were plotted against the average of the 
values from each device and the Oxycon device (Bland–
Altman plots).23 Linear mixed effects models were used to 
compute the upper and lower 95% limits of agreement (LoA) 
of the differences; taking into account multiple sources of 
variation due to patients and activities by modeling these as 
random and fixed effects respectively. Ninety-five percent 
confidence intervals were computed around the limits using 
a bootstrap method.
The two monitors that proved to be the most accurate 
(lowest mean bias and narrowest LoA) in measuring BR 
were selected for further assessment.
Table 1 Monitors’ technical characteristics
Monitor Output Size Position Technology
Monitor 1: Impedance eCg, hr, Br, and Pal 7.5×5.0×2.0 cm, weight 60 g attached to the chest and upper 
abdomen
electrode array 
(impedance)
Monitor 2: PPg Br 56×36×62 mm, weight 54 g Worn on the wrist with a finger 
probe
PPg
Monitor 3: Camera Br and hr n/a Participant was videoed while in 
sitting position
Distance PPg algorithm 
Monitor 4: accel Br and Pal 4.5×3.5×1.3 cm, weight 18 g attached to the upper abdomen just 
below the ribs and taped to the skin
accelerometer
Monitor 5: Chest-band hr, r-r Interval, Br, 
eCg, posture, Pal
•	 Posture
•	 activity level
•	 Peak accel
2.8×0.7 cm, weight 89 g 
(including the chest strap)
Chest strap and an electronics 
module that attaches to the strap
Pressure sensor pad 
and accelerometer
Abbreviations: Br, breathing rate; eCg, electrocardiogram; hr, heart rate; Pal, physical activity level; PPg, photoplethysmography; n/a, not applicable; r-r, distance 
between 2 r peaks on eCg; accel, accelerometer.
Table 2 Protocol followed to assess Br variations during the 
phase 1 of the study
Type of activity Time (min)
lying 4
sitting 2
standing 1
slow 6MWT 6
sitting 3
Fast 6MWT 6
sitting 5
sweeping 4
sitting 2
lifting objects 3
sitting 2
standing and walking 1
Climbing stairs 1
sitting 5
standing and walking 1
Treadmill (flat walking) 4
Treadmill (4% slope) 4
standing and walking 1
sitting 2
Abbreviations: Br, breathing rate; 6MWT, 6 minutes walking test.
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Phase II: performance at home and qualitative 
assessment of acceptability
In phase II, 23 stable patients were recruited and asked to 
wear the two BR monitors simultaneously during waking 
hours over 14 consecutive days. Patients were asked to 
take two 30-min resting periods every day (circa 12:00 h 
and 19:00 h) during which time they wore a pulse oximeter 
and were asked to complete the Borg and modified Medical 
Research Council dyspnea scales. Patients recorded these 
data and rest times in a study diary. After 14 days of monitor-
ing, data were downloaded to a personal computer.
Qualitative assessment
A semi-structured interview was arranged with each patient 
in their home after the monitoring period to explore their 
perceptions of using the technology. The interviews were 
based on an interview guide, which was revised iteratively 
as the study progressed (see the file online supplement in 
Supplementary material for the topic guide, section 2.6).24 
The interviews were conducted by a researcher not involved 
with the quantitative monitoring or analysis to reduce the 
possibility of bias. Interviews were audio-recorded, fully 
transcribed, inductively coded, and analyzed thematically 
to explore the patient’s experience of wearing the BR 
monitors.
Quantitative analysis
Overall BR data were summarized descriptively (mean, 
median, upper and lower quartile, and maximum and mini-
mum). Using daily resting BR data, we established an “at-rest” 
reference range for the COPD population. Normal linear 
mixed models were used to determine the between-patient and 
day-to-day within-patient variation in breathing measurements 
for each device, including the patient as a random effect.
To determine the measurement period of time necessary 
to provide a stable indication of resting BR, we calculated the 
duration of monitoring required to achieve a 95% confidence 
interval half-width of two breaths per minute (bpm) for the 
upper and lower limits of the reference range.
Phase III: ability to capture changes in Br during 
recovery from an aeCOPD
The monitor that performed best in terms of accuracy and 
patient preference (Chest-band) was selected for phase III. 
Patients were recruited during hospital admission with 
AECOPD or by the community respiratory team during 
an AECOPD managed at home. Each patient was asked to 
wear the device from the day of recruitment while in the 
ward (severe AECOPD) or their homes (moderate/severe 
AECOPD), during waking hours, over a period between 
3 and 6 weeks. On completion, data from the monitor were 
downloaded to a personal computer.
The evolution of BR data up to 41 days following 
AECOPD was summarized descriptively and graphically for 
each patient and overall. As in phase II, normal linear mixed 
models were used to determine the between-patient and day-
to-day within-patient variation in “at-rest” BR measurements, 
with the addition of a fixed effect for number of days post-
exacerbation to adjust for changes in BR over time. Very low 
BRs of below 10 bpm or very high values of 40 or above were 
regarded as implausible and excluded from the analysis.
Statistical analyses were performed using R software 
(version 3.2.3) and SAS software (version 21).25,26 Figure 
construction was performed with GraphPad Prism Version 4.0 
and R software.
availability of data and materials
Further information is included in the file online supplement 
in Supplementary material and is available on request from 
the corresponding author.
Results
Phase I. Validation of Br measurements in 
a laboratory setting
The characteristics of the phase I participants are shown in 
Table 3 and the Bland and Altman plots are shown in Figure 1. 
Table 3 Patients characteristics
COPD 
patients 
phase I
COPD 
patients 
phase II
COPD 
patients 
phase III
n 21 23 18
Men (%) 13 (62) 13 (65) 9 (69)
age (years) 68.7, sD 7.9 68.8, sD 7.6 71.5, sD 10.4
height (cm) 166.3, sD 8.4 165.4, sD 11.9 165.5, sD 9.9
Weight (kg) 71.1, sD 17 76.2, sD 22.1 75.5, sD 15.8
BMI (kg/m2) 25.6, sD 5.7 28.6, sD 9.5 27.5, sD 5.1
Pack/year 37.0, sD 18.0 46.5, sD 19.6 53, sD 20.7
mMrC 1.15, sD 1 3.3, sD 0.7
FeV1 (l) 1.4, sD 0.5 1.24, sD 0.5 1.2, sD 0.5
FeV1 (% pred) 47 (59%) 42 (53%) 42 (53%)
FVC (l) 3.0, sD 1.0 2.6, sD 0.7 2.7, sD 1.1
FVC (% pred) 81 (101%) 71 (88%) 75 (94%)
FeV1/FVC 0.5, sD 0.47 0.48, sD 0.45 0.44, sD 0.45
spO2 (%) 92.0, sD 3.7 91.1, sD 4.6
6MWD (m) 432.8, sD 124.7
QMVC (kg) 31.6, sD 9.2
Pal (steps) 4,368, sD 2,270
Abbreviations: 6MWD, 6 minutes walking distance; BMI, body mass index; COPD, 
chronic obstructive pulmonary disease; FeV1, forced expiratory volume in the first 
second; % pred, percent of predicted; FVC, forced vital capacity; mMRC, modified 
Medical research Council dyspnea score; pack/year, cumulative history of smoking; 
Pal, physical activity level; QMVC, quadriceps maximal voluntary contraction; spO2, 
oxygen saturation; sD, standard deviation.
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Monitor 4 (accelerometer [Accel]; bias=−2.18, LoA=−8.63 
to 4.27) and Monitor 5 (Chest-band; bias=−1.60, 
LoA=−9.99 to 6.80) showed lower bias and a narrower 
LoA than Monitor 1 (impedance; bias=−1.18, LoA=−20.07 
to 17.72), Monitor 2 (photoplethysmography [PPG]; 
bias=3.01, LoA=−11.17 to 17.19) and Monitor 3 (Cam-
era; bias=−3.21, LoA=−12.71 to 6.30). Bias and LoA are 
shown in Table 4.
The ability to capture changes in BR was tested using 
BR data obtained at rest (sitting immediately before the 
activity; mean 15.6, SD 1.4 bpm) and during activity (fast 
6 minute walking test [6MWT], slow 6MWT, sweeping, and 
lifting objects; Figure 2; mean 21.0, SD 0.2 bpm). Monitor 
5 (Chest-band) showed the best concordance with the data 
measured by the gold standard and the greatest sensitivity to 
changes in activity. The PAL and HR provided by Monitor 
5 were also validated in phase I (see the file online supple-
ment in Figures S1 and S2). The two devices selected to 
proceed to phase II were Monitor 4 (Accel) and Monitor 5 
(Chest-band).
Figure 1 Validation of BR in a laboratory setting for five monitors.
Notes: Bland and altman plots between Oxicon® Br output and different monitors Br outputs. solid lines represent the bias, and dotted lines represent 95% limits of prediction.
Abbreviations: accel, accelerometer; bpm, breath per minute; Br, breathing rate; PPg, photoplethysmography.
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Phase II. Performance at home and 
qualitative assessment of acceptability
There were design and acceptability issues with both moni-
tors. The adhesive patch used with Monitor 4 (Accel) caused 
skin problems in some people and it did not always keep 
the device in place. Most patients were confident placing 
Monitor 5 (Chest-band) though some had difficulties in fitting 
it comfortably and a few, whose body shape was outside the 
norm, could not wear the device in the recommended position 
and some women had difficulty fitting it under their bra. Some 
patients reported difficulty in removing the Monitor 5 (Chest-
band) device from the chest strap to charge the monitor.
The general preference for patients was for the Monitor 5 
(Chest-band). The main reasons for this were because of 
problems with the adhesive pouch used to keep Monitor 4 
(Accel) in place. The interview schedule included ques-
tions about the utility of the devices and the concept of BR 
monitoring. As neither of the monitors provided any direct 
feedback to the patients (data had to be downloaded and 
processed), patients found it hard to speculate about self- or 
nurse-led monitoring of their breathing. However, most 
agreed in principle that this would be desirable (see the file 
online supplement in Supplementary material for the inter-
view guide, section 2.1).
Out of a possible total of 644 readings, 237 (37%) valid 
resting BR measurements were recorded using Monitor 4 
(Accel), compared to 351 (55%) for Monitor 5 (Chest-band). 
Measured bpm ranged from 9.0 to 30.2 using Monitor 4 
(Accel) and from 9.5 to 45.7 using Monitor 5 (Chest-band) 
(see the file online supplement in Supplementary material 
section 2.2 for data completeness). The overall mean BR was 
21.5 (SD 3.8) for Monitor 4 (Accel) compared to 18.8 (SD 
4.9) for Monitor 5 (Chest-band). The within-patient standard 
deviation of BR was estimated at 2.92 for Monitor 4 (Accel) 
compared to 3.36 for Monitor 5 (Chest-band) (see the file 
online supplement in Supplementary material section 2.3 
Table 4 Bias and limits of agreement of the five monitors
Monitors Bias Limit of agreement
Monitor 1 (Impedance) −1.18 −20.07 to 17.72
Monitor 2 (PPg) 3.01 −11.17 to 17.19
Monitor 3 (Camera) −3.21 −12.71 to 6.30
Monitor 4 (accel) −2.18 −8.63 to 4.27
Monitor 5 (Chest-band) −1.60 −9.99 to 6.80
Abbreviation: PPg, photoplethysmography.
Figure 2 Plots of the mean Oxicon® Br output against the mean output for the other monitors when comparing resting (sitting) with combined activities (fast 6MWT, slow 
6MWT, sweeping, and lifting).
Abbreviations: 6MWT, 6 minute walking test; bpm, breath per minute; PPg photoplethysmography; Br, breathing rate.
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for respiratory rate statistics; see the file supplement tables 
in Table S1 for within-patient variances of BR). At least 
25 days of measurement using Monitor 4 (Accel) would be 
needed for an at rest BR reference range to be estimated with 
sufficient precision (±2 bmp). For Monitor 5 (Chest-band), 
~33 days of measurement would be required. (See the file 
supplement tables in Table S2 for random effects modeling 
of the “at-rest” respiratory rate data for Monitors 4 and 5; 
see the file supplement tables in Table S3a and b [Monitor 5] 
and [Monitor 4] for individual patient 95% reference ranges; 
see section 2.6 and the file supplement tables in Table S4 in 
the Supplementary material for results from normal linear 
mixed models for the association between respiratory rate 
and other variables.)
Monitor 5 (Chest-band) was selected for further testing in 
phase III on the basis of its performance in collecting usable 
data and patients’ preferences.
Phase III. ability to capture changes 
during recovery from an aeCOPD
Monitor 5 (Chest-band) was the only monitor used in this 
phase. A total of 19 patients were recruited into the study, 
one of whom withdrew consent before any monitoring was 
done. Therefore, there were 18 patients with at least one valid 
observation recorded. One patient died during follow-up. 
Five other patients withdrew from the study early. The main 
reason for nonparticipation and withdrawal was that they felt 
too ill to participate or to continue. Two patients (3 and 4) had 
a second AECOPD event during their monitoring period, thus 
providing data from two exacerbations in these patients.
Monitor 5 (Chest-band) also measured physical activ-
ity data (see the file online supplement in Supplementary 
material). We were thus able to exclude those BR observa-
tions where the patient was evidently not at rest, instead of 
relying on a patient report as we had planned. Therefore, for 
the analysis in this phase, we only used BR data for which 
we were confident that the patient was “at rest”.
In total, 109,686 BR observations were recorded as 
valid. The average number of observations per patient was 
6,094 (range 135–28,836; see the file online supplement in 
Supplementary material section 3.2 for descriptive statistics 
of resting respiratory rate).
The within-patient standard deviation was estimated 
to be 3.99 and between-patient standard deviation 2.98 
(see the file online supplement in Supplementary material 
section 3.3 for variation in resting respiratory rate measure-
ments). The plot of the mean BR from all patients suggests 
a gradual decrease in resting BR over time following an 
exacerbation (Figures 3 and see the file online supplement 
in S3). However, this average result masks marked indi-
vidual variation between patients, examples of which are 
shown in Figures 4 and see the file online supplement in 
S4. Additionally, there is a risk that as withdrawals were 
not included in the later time points and any observed 
trend in the mean could be misleading, especially if those 
dropping out did so because they felt too ill to continue. 
As was expected, some did not show changes in BR 
throughout the assessment period (eg, patient 18). The 
Supplementary material (see the file online supplement) 
provides the graphs for all participants recording data for 
at least 5 days.
Interestingly, one patient showed an increase of symp-
toms while being monitored, which resulted in hospital 
admission. The recovery in BR and HR was interrupted and 
an increase in these parameters was seen in the days prior to 
hospitalization (Figure 5).
Discussion
Main findings
We established the accuracy of two novel BR monitors 
compared with the current gold standard, the acceptability 
to the patients of wearing the devices at home and the degree 
to which resting BR varied in the home setting. Of the two 
monitors that we found were valid tools to monitor BR, one 
captured data more reliably and was preferred by patients 
in terms of acceptability and was, therefore, selected for 
phase III where we aimed to detect a change in BR as people 
recovered from COPD exacerbations.
In phase III, we were able to demonstrate a mean gradual 
decrease in resting BR over time following an exacerbation 
in the population studied. However, individual data showed 
Figure 3 evolution of Br shows the overall patient evolution of the Br during the 
recovery.
Abbreviation: Br, breathing rate.
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Figure 4 example of patients during the monitoring period.
Notes: Panel (A) shows patients 6 and 9 who showed improvements during the recovery process in Br and Panel (B) is an example of a patient who did not show 
improvements.
Abbreviations: bpm, breath per minute; Br, breathing rate.
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Figure 5 Monitored patients 3 and 4 during two cycles of aeCOPD.
Abbreviations: bpm, breath per minute; Br, breathing rate; aeCOPD, exacerbations of chronic obstructive pulmonary disease; rr, respiratory rate.
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variation between patients with only a few patients showing 
the expected pattern of a decrease in BR, while for others BR 
remained stable throughout the whole period of assessment. In 
the one patient who was re-hospitalized due to a return of symp-
toms, the monitor captured an increase in BR (and also HR) in 
the days prior to hospitalization confirming that, when changes 
occur, the monitor was capable of capturing the information.
Interpretation of findings in relation to 
previously published work
To our knowledge this is the first evaluation of novel BR 
monitors in COPD against a gold standard in a range of 
people with COPD severity, in their homes. Research explor-
ing the potential of using BR to predict exacerbations was 
published during the course of our study.27 The researchers 
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found that in people on domiciliary oxygen background 
variation was sufficiently low to allow prediction of an exac-
erbation. However, this cohort was probably more sedentary 
than our group, facilitating the measurement of resting BR.
Neither of the monitors in phase II provided immediate 
feedback on BR to the patients, which may have limited 
the potential benefits for the patient. The provision of a 
numerical reading of oxygen saturation is strongly valued 
by patients, who used it to explore their condition, reassure 
themselves about their status, inform their self-management, 
and improve access to professional help.28–30 In the absence 
of feedback, the BR did not assist self-management and 
would have required professional supervision with the 
associated risk of creating dependence.30 Future integra-
tion of these devices into a telehealth system will need 
to address how the readings can be used to support self-
management.28
strengths and limitations of this study
We tested all devices against a recognized gold standard 
and in phase III were able to take advantage of the fact that 
the device we selected could measure energy expenditure to 
establish resting periods clearly. BR changes dramatically 
with different activities, and we only analyzed resting BR 
data. Considerable within-patient variances of resting BR 
were observed, which may have been due to patients re-
exacerbating during their recovery period.
Our study included people with a range of severi-
ties of COPD so that we could establish the utility of 
devices in measuring BR across the spectrum of disease. 
In contrast to phases I and II (in which participants were 
required to be stable), recruitment of patients early after 
the onset of AECOPD for phase III was difficult because 
of the patients’ perception that they were too ill to take 
part in research. Consequently, we believe that some of 
the patients had returned to their baseline levels of BR at 
the time of recruitment, which may have contributed to 
the observation that measurements (BR, but also HR and 
PAL) remained stable in these subjects during the assess-
ment period.
Implications for future research, policy, 
and practice
We have demonstrated that accurately monitoring resting BR 
in ambulatory people with COPD is possible and potentially 
acceptable. The level of compliance with the use of the 
monitors was good particularly among the stable patients 
who participated in phase II who indicated that they would be 
willing to use either sensor for longer periods of time. There 
were some practical concerns related to acceptability (eg, 
skin reactions to adhesives, lights visible through clothing), 
which could be addressed as part of future development to 
customize these monitors for routine domiciliary use, and it 
is this relatively well group (as opposed to those recruited in 
phase 3) for whom a potential intervention would be targeted. 
Our study revealed ways in which acceptability might be 
improved (eg, by providing real-time patient feedback).
We undertook this study to explore the potential of BR 
monitoring in people with COPD with the ultimate aim 
of using such monitoring to improve the timely detection 
and self-management of exacerbations to prevent hospital 
admissions. The substantial background variation presented 
challenges in interpreting the signals of an exacerbation, and 
future development will need to address the detection of small 
changes in the context of background noise.
Monitoring recovery from an AECOPD was a preliminary 
step before embarking on a prospective study to determine if 
such a change was likely to be detectable in the other direction 
(as people at high risk of exacerbation fell ill with AECOPD). 
AECOPDs are heterogeneous and an appropriate approach 
may be in identifying the sub-group of patients in whom 
change in BR is detectable and predictive of exacerbations.1 
Changes in breathlessness,31 BR,27,32 and HR33 increase while 
PALs34 decrease during AECOPD. Our study proved the 
validity of a commercially available monitor to capture these 
parameters, which can help the early identification of patients 
at risk of exacerbations and future hospitalizations in order 
to improve patients’ self-management and management by 
health care professionals.
Conclusions
Accurately monitoring of resting BR is possible in ambulant 
people with COPD. Compliance and acceptability was high 
among those patients who were stable but was challenging 
for some who were very ill, although immediate feedback on 
BR to patients might have improved acceptability. A mean 
fall in resting BR during the recovery phase of an AECOPD 
masked substantial heterogeneity at an individual patient 
level and it was not clear that such changes could reliably be 
identified from normal background variation. A prospective 
study among those at risk of an exacerbation is needed to 
assess changes in BR at the onset of AECOPD.
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